Significant Contracts - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended			6 Months Ended		12 Months Ended
	May 31, 2024	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2019	Dec. 31, 2021
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Non-current deferred revenue		$ 12,583,000			$ 12,583,000		$ 14,012,000
Current deferred revenue		4,759,000			4,759,000		4,105,000
Collaboration Expense		52,131,000	$ 44,636,000		99,097,000	$ 86,828,000
A&R Vertex JDCA [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Percentage of net profits and net losses									40.00%
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Business Combination, Consideration Transferred			70,000,000
Milestone payment receivable							200,000,000
Research milestone payment			70,000,000
Collaboration Expense		52,100,000	44,600,000		99,100,000	86,800,000
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Collaboration Target Options [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payment receivable		410,000,000			410,000,000
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | 2019 Collaboration Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Percentage of exchange payment of research and development costs								50.00%
Maximum potential future payments					775,000,000
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | A&R Vertex JDCA [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Up-front payment received							900,000,000
Percentage of net profits and net losses									60.00%
Current payment due							20,000,000
Revenue		0	70,000,000		0	170,000,000	170,000,000
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Non Ex License Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Up-front payment received				$ 100,000,000
Milestone payment receivable		160,000,000			160,000,000				$ 160,000,000
Research milestone payment			70,000,000
Revenue							100,000,000
Vertex Pharmaceuticals Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Proceeds from letter agreement	$ 43,000,000
Net proceeds from transfer	42.00%
Non-current deferred revenue		12,300,000			12,300,000
Transaction price allocated to remaining performance obligations							12,300,000
Current deferred revenue		0			0		$ 0
Reimbursements from research and license agreements		$ 500,000	$ 2,400,000		1,300,000	$ 5,200,000
Vertex Pharmaceuticals Inc [Member] | A&R Vertex JDCA [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Up-front payment received					$ 100,000,000